亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Microbiome Based Treatment for Cirrhosis Patients

详细技术说明
Cirrhosis is a major cause of death/disability worldwide and the eighth leading cause of death in the US in 2010. Cirrhosis patients have a high likelihood of multiple hospitalizations and developing infections. One major reason is related to dysbiosis or unfavorable microbiome of the gut. Overuse of antibiotics in cirrhosis results in increase of culture-negative and fungal infections from dysbiosis.
*Abstract

From a patient’s microbiome sample screening (16S rRNA bacterial) we can predict which patients:

  • have fungal overgrowth requiring a lower threshold for anti-fungal coverage
  • are unlikely to sustain further antibiotic use
  • are likely to need repletion of their microbiome using:
    • probiotics
    • prebiotics
    • fecal microbial transplant
  • are expected to get re-hospitalized within 90 days
  • to treat with antibiotics or antifungal agents

Clinical Trials: 169 patients, over 90% accuracy identifying/predicting infections

国家/地区
美国

欲了解更多信息,请点击 这里
移动设备